SCHEMBL31225596

SCHEMBL31225596

C#CCCOc1ccc(CO[C@]2(C(=O)OC)C[C@H](OC(C)=O)[C@@H](NC(=O)COC(C)=O)[C@H]([C@H](OC(C)=O)[C@@H](CNC(=O)C3(c4ccc(C(F)(F)F)cc4)CCOCC3)OC(C)=O)O2)cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31225360 0.90 CD22 (0.31) —
SCHEMBL31225159 0.86 CD22 (0.30) —
SCHEMBL31225834 0.84 — —
SCHEMBL31225349 0.83 — —
SCHEMBL31225967 0.82 CD22 (0.40) —
SCHEMBL31225919 0.82 CD22 (0.41) —
SCHEMBL31225602 0.80 CD22 (0.31) —
SCHEMBL31502414 0.78 CD22 (0.39) —
SCHEMBL31225396 0.77 CD22 (0.39) —
SCHEMBL31225847 0.77 CD22 (0.43) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 — — US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 — — WO disclosed
Send feedback